GCC Nursing Guide — Gestational Hypertension & Pre-eclampsia

Classification of Hypertensive Disorders of Pregnancy

Condition	BP Criteria	Proteinuria	Onset	Resolves
Gestational Hypertension	≥140/90 mmHg on 2 occasions ≥4h apart	Absent	>20 weeks gestation	Within 12 weeks postpartum
Pre-eclampsia	≥140/90 mmHg	>300mg/24h OR PCR >30mg/mmol OR dipstick 2+	>20 weeks	Usually resolves postpartum
Severe Pre-eclampsia	≥160/110 mmHg on 2 occasions	May be present; severe features without proteinuria also qualify	>20 weeks	Delivery required
Eclampsia	Any level if seizure occurs	Usually present	>20 weeks or postpartum	After delivery and treatment
Chronic Hypertension	≥140/90 mmHg	Absent initially	<20 weeks OR pre-existing	Persists post-delivery
Superimposed Pre-eclampsia	Worsening hypertension + new proteinuria	New or worsening	On background of chronic hypertension	Partial resolution postpartum

Severe Features of Pre-eclampsia

Any ONE of these features = severe pre-eclampsia — requires urgent intervention and delivery planning.

BP ≥160/110 mmHg on two occasions (≥15 min apart)
Persistent severe headache (not relieved by paracetamol)
Visual disturbances (blurring, flashes — scotomata)
Right upper quadrant (RUQ) or epigastric pain (hepatic capsule tension)
Oliguria (<500 mL/24h or <25 mL/h)
Pulmonary oedema (breathlessness, SpO₂ fall)
Platelet count <100 × 10⁹/L
Creatinine >90 µmol/L (doubling from baseline)
Seizure (= eclampsia)
HELLP syndrome features

Aspirin Prophylaxis — NICE/WHO Guidelines

Low-dose aspirin 75–150 mg daily from 12 weeks gestation reduces pre-eclampsia risk by ~20%.

High-Risk Factors (1 sufficient)

Previous pre-eclampsia or eclampsia
Chronic kidney disease (CKD)
Pre-existing hypertension
Pre-existing diabetes (T1DM or T2DM)
Autoimmune disease (SLE, antiphospholipid syndrome)

Moderate-Risk Factors (≥2 needed)

Nulliparity; BMI ≥35; age ≥40
Multiple pregnancy; family history of pre-eclampsia
Pregnancy interval >10 years

Nursing Assessment Framework

Vital Signs

BP: use calibrated sphygmomanometer; correct cuff size; patient seated; arm at heart level
Record both arms on first assessment; use the higher reading
Frequency: every 15–30 minutes in severe hypertension; 4-hourly if mild
MAP (Mean Arterial Pressure): target <125 mmHg acutely
SpO₂, HR, RR, temperature, GCS

Urine Assessment

Urine dipstick: protein 1+ or more → send MSU + PCR/ACR
24-hour urine collection: protein >300 mg/24h = significant proteinuria
Urine protein:creatinine ratio (PCR) >30 mg/mmol = significant
Hourly urine output: target ≥0.5 mL/kg/h; oliguria <25 mL/h = alert

Investigations

FBC: thrombocytopaenia (HELLP); haemolysis (low Hb, high LDH)
U&E: rising creatinine = renal involvement
LFTs: elevated ALT/AST = hepatic involvement (HELLP)
Clotting: PT/APTT/fibrinogen — DIC in severe HELLP
LDH: elevated in haemolysis (HELLP criterion)
Blood film: fragmented red cells (schistocytes) = microangiopathic haemolysis
Uric acid: elevated in pre-eclampsia (less specific marker)
CTG: foetal monitoring — non-reassuring = urgent obstetric review
USS: foetal growth, liquor volume, umbilical Doppler waveforms

HELLP Syndrome — Diagnosis & Features

HELLP = Haemolysis + Elevated Liver enzymes + Low Platelets. May occur WITHOUT hypertension or proteinuria. Misdiagnosis is common — consider in ANY pregnant woman with RUQ pain, nausea, malaise, or thrombocytopaenia.

Criterion	Laboratory Threshold
H — Haemolysis	Abnormal peripheral blood smear (schistocytes) + LDH >600 IU/L + Bilirubin >1.2 mg/dL
EL — Elevated Liver enzymes	AST >70 IU/L (≥2× upper normal limit)
LP — Low Platelets	Platelets <100 × 10⁹/L (Class 1 <50; Class 2 50–100; Class 3 100–150)

Platelet Transfusion Thresholds in HELLP

Platelets <20 × 10⁹/L AND active bleeding: transfuse platelets
Platelets <50 × 10⁹/L AND planned surgical delivery (CS): transfuse before surgery
Do NOT transfuse prophylactically above these thresholds unless refractory

Antihypertensive Therapy in Pregnancy

Treatment threshold: Treat BP ≥150/100 mmHg in pre-eclampsia. Emergency treatment for BP ≥160/110 mmHg within 30–60 minutes to prevent maternal stroke.

Drug	Route & Dose	Notes	Safety
Labetalol (1st line)	Oral: 100–200 mg TDS/QDS; IV: 20 mg bolus → titrate to 80 mg per dose, max 300 mg	Alpha + beta blocker; fast onset IV; good foetal safety record	Safe — avoid in asthma, heart block
Nifedipine MR (1st line)	Oral: 10–20 mg BD (modified release); emergency: nifedipine IR 10 mg oral	CCB; good BP control; useful oral alternative	Safe — avoid sublingual route (precipitous drop)
Methyldopa	Oral: 250–500 mg TDS	Central alpha-2 agonist; well-established in pregnancy; slower onset	Safe — avoid in depression; not for acute hypertension
Hydralazine	IV: 5 mg bolus every 20 min, max 20 mg	Direct vasodilator; reserve for refractory severe hypertension	Use with caution — risk of maternal hypotension
ACE inhibitors / ARBs	—	CONTRAINDICATED in pregnancy	AVOID — Teratogenic (foetal renal anomalies, oligohydramnios, foetal death)

Magnesium Sulphate — Eclampsia Prevention & Treatment

Magnesium sulphate is the FIRST-LINE treatment for eclamptic seizures — NOT diazepam or phenytoin. It is also used prophylactically in severe pre-eclampsia to prevent seizures.

Regimen (Magpie Protocol)

Loading dose: 4 g IV over 10–15 minutes
Maintenance: 1 g/h IV infusion (diluted in 0.9% NaCl)
Continue for 24 hours after delivery OR 24 hours after last seizure
If seizure recurs: 2 g IV bolus over 5 minutes

Toxicity Monitoring — CHECK BEFORE EACH DOSE

Patellar reflexes: FIRST sign of toxicity — absent reflexes = STOP infusion immediately
Respiratory rate: must be ≥12–14/min before giving dose
Urine output: must be ≥25 mL/h (magnesium renally cleared)
Serum Mg levels: therapeutic 2–3.5 mmol/L; toxic >5 mmol/L
Antidote: Calcium gluconate 1g IV (10 mL of 10%) over 3 minutes

Nursing mnemonic for MgSO₄ monitoring: RR (Respiratory Rate ≥12), Reflexes (patellar present), Renal output (urine ≥25 mL/h). If ANY absent — STOP infusion and give calcium gluconate antidote.

Eclampsia Emergency Management

Step	Action
1. Airway	Position in left lateral (recovery); jaw thrust if needed; do NOT insert anything in mouth during seizure
2. Call for help	Emergency obstetric team, anaesthetist, neonatologist — activate MET/emergency call
3. Oxygen	High-flow O₂ via non-rebreather mask 15 L/min; SpO₂ monitoring
4. IV access	Large-bore IV × 2; take bloods (FBC, clotting, U&E, LFTs, LDH, blood type & cross-match)
5. Magnesium sulphate	4g IV over 10–15 minutes — FIRST-LINE anticonvulsant; 1g/h maintenance
6. Antihypertensive	IV labetalol or oral/IV nifedipine if BP ≥160/110 mmHg
7. CTG monitoring	Foetal monitoring: foetal bradycardia common during/after seizure — usually transient
8. Delivery	Definitive treatment = delivery; timing depends on gestation and maternal/foetal condition
9. Corticosteroids	Betamethasone 12 mg IM × 2 doses (24h apart) if gestation <34 weeks — foetal lung maturation

Fluid Management & Postpartum Care

Fluid restriction in severe pre-eclampsia: Risk of pulmonary oedema — restrict IV fluids to 80 mL/h (1 mL/kg/h) unless haemorrhage. Avoid aggressive fluid loading.

Continue BP monitoring for at least 72 hours postpartum (risk of late-onset eclampsia)
BP monitoring essential up to 6 weeks postpartum — risk of hypertension persists
Avoid NSAIDs postpartum — raises BP and may worsen renal function
Paracetamol is safe for analgesia postpartum in pre-eclampsia
Breastfeeding: labetalol, nifedipine, enalapril are compatible with breastfeeding
Contraception: AVOID combined oral contraceptive pill (oestrogen raises BP); progesterone-only methods safe
Long-term risk: pre-eclampsia is a risk factor for future cardiovascular disease — counsel and follow up

Complications Summary

Complication	Features	Management
Eclampsia	Tonic-clonic seizures; may occur antepartum, intrapartum, or postpartum (<48h most common; rare up to 4 weeks post)	MgSO₄ loading dose; secure airway; antihypertensive; deliver when stable
HELLP Syndrome	RUQ pain, nausea/vomiting, malaise, jaundice; thrombocytopaenia may cause bleeding	Delivery is definitive; corticosteroids (dexamethasone) may be used; platelet transfusion as per thresholds; HDU/ICU care
Cerebral haemorrhage	Most common cause of maternal death in severe pre-eclampsia/eclampsia; caused by uncontrolled severe hypertension	Urgent BP control is the key prevention; neurosurgical consultation if confirmed
Pulmonary oedema	Fluid overload, low oncotic pressure (hypoalbuminaemia), cardiac dysfunction	Furosemide IV; O₂ therapy; sitting upright; fluid restriction; urgent delivery
Placental abruption	Vasospasm and endothelial damage increase abruption risk; foetal distress/death	Emergency CS if foetal compromise; stabilise mother
DIC	Especially in HELLP + placental abruption; consumptive coagulopathy	FFP, cryoprecipitate, platelets as required; treat underlying cause
Acute Kidney Injury (AKI)	Renal cortical necrosis in severe cases; oliguria common	Strict fluid management; avoid nephrotoxics; consider dialysis if severe

Pre-eclampsia in the GCC Context

The GCC region has elevated pre-eclampsia risk due to high rates of obesity, T2DM, and multiple pregnancies (IVF). Maternal mortality surveillance programmes are mandated by health authorities.

~8–10%Pre-eclampsia Rate GCC

≥25%GCC Adult Obesity Rate

DHA / DOHHigh-Risk OB Protocols

DHA & DOH High-Risk Obstetric Protocols ▼

All pregnant women assessed for pre-eclampsia risk at booking (first trimester)
First-trimester combined screening (BP, uterine artery Doppler, PAPP-A, PlGF) for early risk stratification
High-risk women referred to maternal-foetal medicine (MFM) specialist clinics
Aspirin prophylaxis prescribed by 16 weeks in eligible patients
Mandatory MgSO₄ protocol in all DHA-accredited hospitals for severe pre-eclampsia/eclampsia
Maternal mortality review committee — all deaths reviewed
Obstetric HDU designated areas in tertiary centres (Dubai, Abu Dhabi, Riyadh, Doha)

Ramadan & Antihypertensive Timing ▼

Pregnant women with hypertension who wish to fast during Ramadan require specialist counselling:

Modified-release (MR) formulations preferred — once-daily dosing reduces compliance problems during fasting
Nifedipine MR: single daily dose at Iftar is appropriate in well-controlled mild hypertension
Labetalol: BD or TDS dosing — adjust timing to Iftar and Suhoor
Severe pre-eclampsia or eclampsia history: strongly advise AGAINST fasting
BP monitoring at home with validated cuffs; attend antenatal clinic breaks-fast if BP ≥160/110
Dehydration risk in hot GCC climates — increases cardiovascular risk; increased risk of placental ischaemia

Cultural & Nursing Considerations ▼

Family-centred care: explain condition to husband/family (key decision-makers in GCC culture)
Same-gender care preference: ensure female doctors/nurses for obstetric examinations where possible
Language: Arabic-speaking nurses or interpreter services essential for informed consent
High GCC IVF rate → multiple pregnancies → higher pre-eclampsia risk — monitor vigilantly
High T2DM prevalence → gestational diabetes + hypertension frequently co-exist
Expat nursing workforce must be trained on GCC-specific protocols (MgSO₄ preparation, antihypertensive protocols)

High-Yield Exam Facts for DHA / DOH / HAAD / SCFHS / QCHP

Gestational hypertension: BP ≥140/90 after 20 weeks, NO proteinuria, resolves by 12 weeks postpartum
Pre-eclampsia = hypertension + proteinuria (>300mg/24h or PCR >30 mg/mmol) after 20 weeks
HELLP = Haemolysis + Elevated Liver enzymes + Low Platelets — can occur WITHOUT hypertension
Magnesium sulphate: 4g loading IV over 10–15 min + 1g/h maintenance
MgSO₄ is FIRST-LINE for eclamptic seizures — NOT diazepam
Magnesium toxicity: FIRST sign = loss of patellar reflexes (check before every dose)
Antidote for MgSO₄ toxicity: Calcium gluconate 1g IV (10 mL of 10%) over 3 minutes
ACE inhibitors/ARBs are CONTRAINDICATED in pregnancy
First-line antihypertensives in pregnancy: labetalol, nifedipine MR, methyldopa
Aspirin 75–150mg from 12 weeks: ≥1 high-risk factor (previous PET, CKD, HTN, DM, autoimmune)
Definitive treatment of pre-eclampsia = delivery
Corticosteroids (betamethasone) if <34 weeks for foetal lung maturation
Postpartum: BP risk continues up to 6 weeks; avoid NSAIDs (raise BP)

Practice MCQs

1. A 30-year-old primigravida at 32 weeks gestation has a BP of 165/112 mmHg on two readings, proteinuria 2+ on dipstick, and complains of a persistent headache. What is the most appropriate immediate nursing action?

A. Administer oral labetalol and reassess in 4 hours

B. Reassure the patient and record BP in 1 hour

C. Activate emergency obstetric team, establish IV access, prepare MgSO₄ and IV antihypertensive

D. Commence 24-hour urine collection before any treatment

Correct: C. This patient has severe pre-eclampsia (BP ≥160/110 + proteinuria + headache). This is an obstetric emergency. Immediate actions include calling the team, IV access, MgSO₄ prophylaxis, and urgent antihypertensive therapy within 30–60 minutes.

2. A patient receiving IV magnesium sulphate infusion for severe pre-eclampsia develops absent patellar reflexes and a respiratory rate of 10/min. What is the priority intervention?

A. Reduce the infusion rate by half

B. STOP the infusion immediately and administer calcium gluconate 1g IV over 3 minutes

C. Administer naloxone IV

D. Continue infusion and monitor closely

Correct: B. Absent patellar reflexes is the FIRST sign of MgSO₄ toxicity. Combined with respiratory depression (RR <12), this is a toxicity emergency. STOP the infusion immediately and give calcium gluconate 1g IV as the antidote.

3. A pregnant patient at 28 weeks develops a tonic-clonic seizure. What is the FIRST-LINE pharmacological treatment for eclampsia?

A. Diazepam IV 10 mg

B. Magnesium sulphate 4g IV over 10–15 minutes

C. Phenytoin IV loading dose

D. Lorazepam IV 4 mg

Correct: B. Magnesium sulphate (4g IV loading dose over 10–15 minutes) is the FIRST-LINE treatment for eclamptic seizures — not diazepam or phenytoin. This is a critical exam point tested across DHA, DOH, and SCFHS licensing exams.

4. Which antihypertensive is CONTRAINDICATED during pregnancy?

A. Labetalol

B. Methyldopa

C. Enalapril (ACE inhibitor)

D. Nifedipine (modified release)

Correct: C. ACE inhibitors (and ARBs) are CONTRAINDICATED in pregnancy due to teratogenicity — causing foetal renal anomalies, oligohydramnios, skull hypoplasia, and foetal/neonatal death. Safe alternatives are labetalol, nifedipine MR, and methyldopa.